320 related articles for article (PubMed ID: 28513532)
1. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
[TBL] [Abstract][Full Text] [Related]
2. Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Tonetti CR; de Souza-Araújo CN; Yoshida A; da Silva RF; Alves PCM; Mazzola TN; Derchain S; Fernandes LGR; Guimarães F
Cells; 2021 Jul; 10(7):. PubMed ID: 34359872
[TBL] [Abstract][Full Text] [Related]
3. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
4. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
Liu M; Xie J; Zhao S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
[TBL] [Abstract][Full Text] [Related]
5. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
Zhu Q; Wu X; Wu Y; Wang X
Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
[TBL] [Abstract][Full Text] [Related]
6. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
7. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
8. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
[TBL] [Abstract][Full Text] [Related]
10. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
11. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.
Yigit R; Figdor CG; Zusterzeel PL; Pots JM; Torensma R; Massuger LF
Eur J Cancer; 2011 Aug; 47(12):1883-9. PubMed ID: 21514148
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia.
da Silva RF; Petta CA; Derchain SF; Alici E; Guimarães F
Hum Immunol; 2014 Aug; 75(8):777-84. PubMed ID: 24882570
[TBL] [Abstract][Full Text] [Related]
14. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
15. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
Felices M; Chu S; Kodal B; Bendzick L; Ryan C; Lenvik AJ; Boylan KLM; Wong HC; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2017 Jun; 145(3):453-461. PubMed ID: 28236454
[TBL] [Abstract][Full Text] [Related]
16. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
Kumar P; Ranmale S; Mehta S; Tongaonkar H; Patel V; Singh AK; Mania-Pramanik J
J Ovarian Res; 2023 Jun; 16(1):114. PubMed ID: 37322531
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma.
Xie X; Ye D; Chen H; Lu W; Cheng B; Zhong H
Int J Gynaecol Obstet; 2004 May; 85(2):151-8. PubMed ID: 15099777
[TBL] [Abstract][Full Text] [Related]
18. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
19. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]